What is Leerink Partnrs’ Forecast for RXRX FY2024 Earnings?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) – Equities researchers at Leerink Partnrs reduced their FY2024 earnings estimates for shares of Recursion Pharmaceuticals in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($1.48) per share for the year, down from their previous estimate of ($1.45). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q4 2024 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue for the quarter was up 147.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.43) earnings per share.

A number of other research analysts also recently issued reports on RXRX. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp lowered their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.75.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $7.33 on Friday. The stock has a market cap of $2.86 billion, a PE ratio of -4.79 and a beta of 0.85. Recursion Pharmaceuticals has a 52-week low of $5.60 and a 52-week high of $15.74. The business has a 50-day simple moving average of $6.90 and a 200-day simple moving average of $6.94. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals during the third quarter worth $25,000. Decker Retirement Planning Inc. acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth about $26,000. GAMMA Investing LLC grew its stake in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after acquiring an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the last quarter. Finally, KBC Group NV lifted its stake in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. The trade was a 0.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,894 shares of company stock worth $279,279 over the last three months. 15.75% of the stock is currently owned by corporate insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.